Photocure ASA (0IMT) Share Price & Analysis

1 Followers

0IMT Stock Chart & Stats

kr 42.00kr 0.08(0.18%)

At close: Nov 11 4:30 PM GMT

Day’s Range: NOK 42.00 - NOK 42.60
52-Week Range: NOK 41.93 - NOK 79.60
Previous Close: NOK 41.93
Volume: N/A
Average Volume (3M): 2,621
Market Cap: NOK 1.11B
Enterprise Value: NOK 1.37B
Total Cash (Recent Filing): NOK 259.54M
Total Debt (Recent Filing): NOK 0
Price to Earnings (P/E): 22.8
Beta: 0.30
Next Earnings: Feb 24, 2027 (Est.)
EPS Estimate: N/A
Last Dividend Ex-Date: May 23, 2013
Dividend Yield: N/A

Photocure ASA News

Photocure’s AssureMDx Excluded From New Medicare Coverage Guidance

An announcement from Photocure ASA ( ($PHCUF) ) is now available. Photocure said AssureMDx was not included in Novitas’ November 6 local coverage determination for urine-based biomarkers in patients with

3d agoPHS PHCUF

Photocure ASA Earnings Call Signals Ambitious Growth

Photocure ASA (($NO:PHO)) has held its Q3 earnings call. Read on for the main highlights of the call. Photocure ASA’s latest earnings call struck a cautiously upbeat tone, as management

2w agoPHS PHCUF

Photocure lifts 2026 growth outlook as it builds broader bladder cancer diagnostics platform

Photocure ASA ( ($PHCUF) ) has issued an update. Photocure reported third‑quarter 2026 Hexvix/Cysview revenues of NOK 134.2 million, broadly flat year‑on‑year, with total revenues rising to NOK 140.9 million

2w agoPHS PHCUF

Photocure Grants Share Options to New CFO Under Long-Term Incentive Plan

The latest announcement is out from Photocure ASA ( ($PHCUF) ). Photocure ASA has granted 200,000 share options to its new Chief Financial Officer, Dennis Camporeale, at an exercise price

2w agoPHS PHCUF

Photocure Strengthens Executive Team With Appointment of Veteran CFO

The latest update is out from Photocure ASA ( ($PHCUF) ). Photocure ASA has appointed Dennis Camporeale as Chief Financial Officer, effective October 26, 2026, strengthening its executive team as

3w agoPHS PHCUF

Photocure Sets Date for Third-Quarter 2026 Results and Investor Webcast

An update from Photocure ASA ( ($PHCUF) ) is now available. Photocure ASA will publish its third-quarter 2026 financial results on 28 October at 08:00 CET and follow up with

3w agoPHS PHCUF

FDA Move to Ease Regulatory Pathway Seen as Catalyst for Photocure’s Bladder Cancer Technology

The latest announcement is out from Photocure ASA ( ($PHCUF) ). Photocure ASA reported that the U.S. Food and Drug Administration has issued a proposed order to reclassify cystoscopic systems

3M agoPHS PHCUF

Photocure Study Finds Blue Light Cystoscopy Boosts Bladder Cancer Detection Without Raising Costs

An announcement from Photocure ASA ( ($PHCUF) ) is now available. Photocure ASA reported new real-world evidence showing that blue light cystoscopy using Hexvix/Cysview improves detection of non-muscle-invasive bladder cancer,

3M agoPHS PHCUF

Photocure Board Members Boost Shareholdings, Signaling Confidence in Uro-Oncology Strategy

Photocure ASA ( ($PHCUF) ) has provided an update. Board chairman Dylan Hallerberg and board member Neal Shore have increased their stakes in Photocure ASA through share purchases on the

3M agoPHS PHCUF

Photocure escalates arbitration in Cevira milestone dispute with Asieris

The latest announcement is out from Photocure ASA ( ($PHCUF) ). Photocure ASA is a Norway-based commercial diagnostic company focused on uro-oncology precision diagnostics, delivering technologies that improve detection and

3M agoPHS PHCUF

0IMT FAQ

What was Photocure ASA’s price range in the past 12 months?

Photocure ASA lowest share price was kr 41.93 and its highest was kr 79.60 in the past 12 months.

What is Photocure ASA’s market cap?

Photocure ASA’s market cap is kr 1.11B.

When is Photocure ASA’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Photocure ASA’s earnings last quarter?

Photocure ASA released its earnings results on Oct 28, 2026. The company reported -kr 0.97 earnings per share for the quarter.

Is Photocure ASA overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Photocure ASA pay dividends?

Photocure ASA pays a dividend of kr 2 which represents an annual dividend yield of ―. See more information on Photocure ASA dividends here

What is Photocure ASA’s EPS estimate?

Photocure ASA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Photocure ASA have?

Photocure ASA has 27,120,820 shares outstanding.

What happened to Photocure ASA’s price movement after its last earnings report?

Photocure ASA reported an EPS of -kr 0.97 in its last earnings report. Following the earnings report the stock price went down -4.541%.

Which hedge fund is a major shareholder of Photocure ASA?

Currently, no hedge funds are holding shares in GB:0IMT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Photocure ASA

Photocure ASA is a specialized pharmaceutical enterprise focused on the development, manufacturing, commercialization, and distribution of medicinal products. Its operational footprint extends across multiple European nations, including the Nordic region, Germany, France, Austria, the United Kingdom, the Netherlands, and Italy, in addition to the United States. The company's primary offering, Hexvix/Cysview, aids in the identification and ongoing management of bladder cancer. Moreover, Photocure is actively progressing Cevira, a therapeutic agent in development targeting human papilloma virus (HPV) infections and pre-cancerous lesions of the cervix. The firm distributes its products to pharmaceutical wholesalers, pharmacies, and healthcare institutions through collaborative licensing arrangements. Founded in 1993, Photocure ASA maintains its corporate headquarters in Oslo, Norway.

Photocure ASA (0IMT) Earnings & Revenues

Historic Earnings Reports

0IMT Company Deck

0IMT Earnings Call

Q3 2026

0:00 / 0:00

Earnings Call SentimentPositive

The call was predominantly positive. Photocure reported 7% constant-currency product revenue growth, strong unit and active-account expansion, improving adjusted EBITDA, continued European and North American momentum, progress on FDA reclassification and OEM access, and multiple long-term growth initiatives. The main negatives were foreign-exchange pressure, a quarterly net loss, higher operating expenses, pending CMS and FDA decisions, expected near-term AssureMDx operating losses, and uncertainty around potential generic competition. Management nevertheless raised 2026 guidance and reiterated substantial long-term growth and margin targets.

View all GB:0IMT earnings summaries

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	6	1	15
Technical Analysis	6	1	3
Moving Averages	0	0	12

Technical Analysis >

Similar Stocks

Stocks similar to GB:0IMT
Company	Price & Change	Follow
PHCUFPhotocure ASA
EGRXEagle Pharmaceuticals
OMEROmeros
TNXPTonix Pharma
ONCYOncolytics Biotech
PFEPfizer

Compare GB:0IMT Stocks >

Ownership Overview

0.22% Mutual Funds
99.40% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

0IMT Stock Chart & Stats

Photocure ASA News

Photocure’s AssureMDx Excluded From New Medicare Coverage Guidance

Photocure ASA Earnings Call Signals Ambitious Growth

Photocure lifts 2026 growth outlook as it builds broader bladder cancer diagnostics platform

Photocure Grants Share Options to New CFO Under Long-Term Incentive Plan

Photocure Strengthens Executive Team With Appointment of Veteran CFO

Photocure Sets Date for Third-Quarter 2026 Results and Investor Webcast

FDA Move to Ease Regulatory Pathway Seen as Catalyst for Photocure’s Bladder Cancer Technology

Photocure Study Finds Blue Light Cystoscopy Boosts Bladder Cancer Detection Without Raising Costs

Photocure Board Members Boost Shareholdings, Signaling Confidence in Uro-Oncology Strategy

Photocure escalates arbitration in Cevira milestone dispute with Asieris

0IMT FAQ

Company Description

Photocure ASA

Photocure ASA (0IMT) Earnings & Revenues

0IMT Company Deck

0IMT Earnings Call

Earnings Call Sentiment|Positive

Technical Analysis

Overall Consensus

Similar Stocks

Ownership Overview

Popular Stocks

Become an Expert with TipRanks Premium

Earnings Call SentimentPositive